Cargando…
Design, synthesis, and in vitro evaluation of aza-peptide aldehydes and ketones as novel and selective protease inhibitors
Aza-peptide aldehydes and ketones are a new class of reversible protease inhibitors that are specific for the proteasome and clan CD cysteine proteases. We designed and synthesised aza-Leu derivatives that were specific for the chymotrypsin-like active site of the proteasome, aza-Asp derivatives tha...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470110/ https://www.ncbi.nlm.nih.gov/pubmed/32633155 http://dx.doi.org/10.1080/14756366.2020.1781107 |
_version_ | 1783578520825364480 |
---|---|
author | Corrigan, Thomas S. Lotti Diaz, Leilani M. Border, Sarah E. Ratigan, Steven C. Kasper, Kayla Q. Sojka, Daniel Fajtova, Pavla Caffrey, Conor R. Salvesen, Guy S. McElroy, Craig A. Hadad, Christopher M. Doğan Ekici, Özlem |
author_facet | Corrigan, Thomas S. Lotti Diaz, Leilani M. Border, Sarah E. Ratigan, Steven C. Kasper, Kayla Q. Sojka, Daniel Fajtova, Pavla Caffrey, Conor R. Salvesen, Guy S. McElroy, Craig A. Hadad, Christopher M. Doğan Ekici, Özlem |
author_sort | Corrigan, Thomas S. |
collection | PubMed |
description | Aza-peptide aldehydes and ketones are a new class of reversible protease inhibitors that are specific for the proteasome and clan CD cysteine proteases. We designed and synthesised aza-Leu derivatives that were specific for the chymotrypsin-like active site of the proteasome, aza-Asp derivatives that were effective inhibitors of caspases-3 and -6, and aza-Asn derivatives that inhibited S. mansoni and I. ricinus legumains. The crystal structure of caspase-3 in complex with our caspase-specific aza-peptide methyl ketone inhibitor with an aza-Asp residue at P1 revealed a covalent linkage between the inhibitor carbonyl carbon and the active site cysteinyl sulphur. Aza-peptide aldehydes and ketones showed no cross-reactivity towards cathepsin B or chymotrypsin. The initial in vitro selectivity of these inhibitors makes them suitable candidates for further development into therapeutic agents to potentially treat multiple myeloma, neurodegenerative diseases, and parasitic infections. |
format | Online Article Text |
id | pubmed-7470110 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-74701102020-09-15 Design, synthesis, and in vitro evaluation of aza-peptide aldehydes and ketones as novel and selective protease inhibitors Corrigan, Thomas S. Lotti Diaz, Leilani M. Border, Sarah E. Ratigan, Steven C. Kasper, Kayla Q. Sojka, Daniel Fajtova, Pavla Caffrey, Conor R. Salvesen, Guy S. McElroy, Craig A. Hadad, Christopher M. Doğan Ekici, Özlem J Enzyme Inhib Med Chem Short Communication Aza-peptide aldehydes and ketones are a new class of reversible protease inhibitors that are specific for the proteasome and clan CD cysteine proteases. We designed and synthesised aza-Leu derivatives that were specific for the chymotrypsin-like active site of the proteasome, aza-Asp derivatives that were effective inhibitors of caspases-3 and -6, and aza-Asn derivatives that inhibited S. mansoni and I. ricinus legumains. The crystal structure of caspase-3 in complex with our caspase-specific aza-peptide methyl ketone inhibitor with an aza-Asp residue at P1 revealed a covalent linkage between the inhibitor carbonyl carbon and the active site cysteinyl sulphur. Aza-peptide aldehydes and ketones showed no cross-reactivity towards cathepsin B or chymotrypsin. The initial in vitro selectivity of these inhibitors makes them suitable candidates for further development into therapeutic agents to potentially treat multiple myeloma, neurodegenerative diseases, and parasitic infections. Taylor & Francis 2020-07-07 /pmc/articles/PMC7470110/ /pubmed/32633155 http://dx.doi.org/10.1080/14756366.2020.1781107 Text en © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Communication Corrigan, Thomas S. Lotti Diaz, Leilani M. Border, Sarah E. Ratigan, Steven C. Kasper, Kayla Q. Sojka, Daniel Fajtova, Pavla Caffrey, Conor R. Salvesen, Guy S. McElroy, Craig A. Hadad, Christopher M. Doğan Ekici, Özlem Design, synthesis, and in vitro evaluation of aza-peptide aldehydes and ketones as novel and selective protease inhibitors |
title | Design, synthesis, and in vitro evaluation of aza-peptide aldehydes and ketones as novel and selective protease inhibitors |
title_full | Design, synthesis, and in vitro evaluation of aza-peptide aldehydes and ketones as novel and selective protease inhibitors |
title_fullStr | Design, synthesis, and in vitro evaluation of aza-peptide aldehydes and ketones as novel and selective protease inhibitors |
title_full_unstemmed | Design, synthesis, and in vitro evaluation of aza-peptide aldehydes and ketones as novel and selective protease inhibitors |
title_short | Design, synthesis, and in vitro evaluation of aza-peptide aldehydes and ketones as novel and selective protease inhibitors |
title_sort | design, synthesis, and in vitro evaluation of aza-peptide aldehydes and ketones as novel and selective protease inhibitors |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7470110/ https://www.ncbi.nlm.nih.gov/pubmed/32633155 http://dx.doi.org/10.1080/14756366.2020.1781107 |
work_keys_str_mv | AT corriganthomass designsynthesisandinvitroevaluationofazapeptidealdehydesandketonesasnovelandselectiveproteaseinhibitors AT lottidiazleilanim designsynthesisandinvitroevaluationofazapeptidealdehydesandketonesasnovelandselectiveproteaseinhibitors AT bordersarahe designsynthesisandinvitroevaluationofazapeptidealdehydesandketonesasnovelandselectiveproteaseinhibitors AT ratiganstevenc designsynthesisandinvitroevaluationofazapeptidealdehydesandketonesasnovelandselectiveproteaseinhibitors AT kasperkaylaq designsynthesisandinvitroevaluationofazapeptidealdehydesandketonesasnovelandselectiveproteaseinhibitors AT sojkadaniel designsynthesisandinvitroevaluationofazapeptidealdehydesandketonesasnovelandselectiveproteaseinhibitors AT fajtovapavla designsynthesisandinvitroevaluationofazapeptidealdehydesandketonesasnovelandselectiveproteaseinhibitors AT caffreyconorr designsynthesisandinvitroevaluationofazapeptidealdehydesandketonesasnovelandselectiveproteaseinhibitors AT salvesenguys designsynthesisandinvitroevaluationofazapeptidealdehydesandketonesasnovelandselectiveproteaseinhibitors AT mcelroycraiga designsynthesisandinvitroevaluationofazapeptidealdehydesandketonesasnovelandselectiveproteaseinhibitors AT hadadchristopherm designsynthesisandinvitroevaluationofazapeptidealdehydesandketonesasnovelandselectiveproteaseinhibitors AT doganekiciozlem designsynthesisandinvitroevaluationofazapeptidealdehydesandketonesasnovelandselectiveproteaseinhibitors |